Compare UTHR & ALB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | ALB |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | United States |
| Employees | N/A | 7800 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 20.7B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | ALB |
|---|---|---|
| Price | $543.40 | $170.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $567.57 | $179.74 |
| AVG Volume (30 Days) | 391.7K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.85% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 5.82 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $6.39 | $12.12 |
| Revenue Next Year | $14.18 | $5.74 |
| P/E Ratio | $93.80 | ★ N/A |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $272.18 | $55.90 |
| 52 Week High | $609.35 | $221.00 |
| Indicator | UTHR | ALB |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 50.04 |
| Support Level | $534.97 | $167.98 |
| Resistance Level | $542.66 | $183.34 |
| Average True Range (ATR) | 12.84 | 7.35 |
| MACD | -1.39 | -0.38 |
| Stochastic Oscillator | 15.92 | 73.30 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants.